Medtech under pressure

Over 200 representatives from the Swiss medtech sector travelled to Lugano to discuss the latest developments. Focus was on the growing global challenges, as well as issues facing Switzerland in its bid to uphold its position as a leading medtech hub. «In times of rising uncertainty, stable partnerships are becoming increasingly important – in particular our relations with the European Union,» said Federal Councillor Ignazio Cassis in his keynote address.

In his opening speech, Swiss Medtech President Damian Mueller highlighted Switzerland’s traditional strengths of legal clarity, entrepreneurial freedom, and streamlined regulations. These should never be taken for granted – and must be defended with vigour! «Business, political administrations, and the authorities must work more closely together once more. What’s needed are clear domestic policy decisions promoting Switzerland as a business location – not additional burdens for an industry already under intense pressure,» said Damian Mueller.

Bilateral III essential for the medtech sector
The European Union (EU) is the Swiss medical technology sector’s most important trading partner: around 50% of all exports go to the EU, and one in three of the over 70,000 industry jobs depends directly on orders from the EU. A recent survey by gfs.bern highlights the importance of bilateral relations: over 70% of medtech companies regard the Switzerland-EU package as essential for their own business, _ and over 80% for Switzerland’s competitiveness as a business location. «Direct access to the EU single market is crucial for the sector. Access, however, has been restricted since negotiations broke down in May 2021 – with serious consequences: the additional red tape is costing our industry billions,» says Adrian Hunn, Director of Swiss Medtech.

Seize opportunities – strengthen Switzerland’s position
Over three years ago, Parliament instructed the Federal Council to revise legislation so that medical devices approved by the US Food and Drug Administration (FDA) would also be recognised on par with those certified by the EU. This would enable Switzerland to target, and enhance its appeal as a business location, while continuing to safeguard patient care. «But instead of embracing this clear mandate as an opportunity, the relevant authorities are dragging their feet. Efforts are ongoing – yet I see a lack of initiative, pace and pragmatic thinking,» criticises Damian Mueller, the author of the parliamentary mandate.

No additional burdens
The planned introduction of a further new fee on medical devices to fund the Swissmedic (the Swiss) is also creating irritation within the industry. Adrian Hunn is highly critical: «The agency is clearly attempting to offload its recent financial problems onto the industry. This is the wrong approach. Mistakes can happen, but passing the consequences on to the industry after the fact is unacceptable.» The planned levy would amount to approximately 25 million Swiss francs annually – which corresponds exactly to the current Swiss Therapeutic Products Agency deficit.